Basilea reports data from poster presentations at ESMO Virtual Congress 2020
- Gene expression data may explain differences inclinical adverse event profiles ofFGFR inhibitors
- Antitumor activity of derazantinibin preclinical cancer models with FGFR aberrationssupportsplanned gastric cancerstudy
- Full resultsfrom the completed phase 1 study in patients with brain cancer underscores the potential for lisavanbulin to be developed in a targeted patient populationusing end-binding protein 1 (EB1) as a patient selection criterion
Basel, Switzerland, September22, 2020
Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
A preclinical study showed that treatment-specific gene expression patterns in tumor models may help elucidating the biological processes driving differences in the clinical adverse event profiles of FGFR inhibitors. Moreover, the results from this study may explain low rates of adverse events reported with derazantinib for retinal events, mucositis and nail toxicities.
Results from a series of preclinical efficacy models of breast, colorectal, head & neck, lung, ovarian and gastric cancer with confirmed FGFR1-3 genetic aberrations, showed that FGFR2-fusion-positive gastric cancer models were particularly sensitive to treatment with derazantinib. In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib. The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
Full results from a phase 1 study with once-daily oral lisavanbulin in adult patients with recurrent glioblastoma (GBM), or high-grade glioma, showed an overall clinical benefit rate of 44% at six months at daily doses of 25-30 mg. There was an exceptional long-lasting response in a patient, whose tumor tissue was positive for end-binding protein 1 (EB1), a previously identified response predictive biomarker for lisavanbulin in preclinical studies. A phase 2 expansion study will be initiated shortly, which will use EB1-positivity as a patient selection criterion.1 Lisavanbulin is dosed at the recommended phase 2 dose of 25 mg/day in this phase 2 study in patients with recurrent GBM. The prevalence of EB1-positivity in GBM is estimated at 2-5%.
Dr. Marc Engelhardt, Chief Medical Officer, said: “The results presented at ESMO support our differentiation strategy for derazantinib, which is based on its unique kinase inhibition profile and its clinical safety profile. They also provide the preclinical rationale for our decision to initiate a clinical study of derazantinib alone and in combination with other therapies in patients with advanced gastric cancer. The full results from the completed phase 1 study with lisavanbulin underscore its potential to be developed in a targeted patient population. Our initial focus will be on glioblastoma. We may decide to explore other tumor types upon achieving clinical validation of EB1 as a response-predictive biomarker in glioblastoma.”
|The following e-posters were presentedat ESMO Virtual Congress 2020:|
|1960P||Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: an analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models.|
|541P||Derazantinib (DZB), an oral Fibroblast Growth Factor Receptor inhibitor (FGFRi), shows promising activity in PDX-tumor models with aberrations in FGFR1-3|
|382P||The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase 1 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)|
For further information, please visit https://www.esmo.org/meetings/esmo-virtual-congress-2020
Derazantinib is an investigational orally administered small-molecule FGFR kinase inhibitor with strong activity against FGFR1, 2, and 3.2 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.3 In these cancers, FGFR genetic aberrations are found in a range of 5% to 30%.4
Derazantinib also inhibits the colony-stimulating-factor-1-receptor kinase (CSF1R).2, 5 CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages and therefore has been identified as a potential target for anti-cancer drugs.6 Preclinical data has shown that tumor macrophage depletion through CSF1R blockade renders tumors more responsive to T-cell checkpoint immunotherapy, including approaches targeting PD-L1/PD-1.7,8
Derazantinib has demonstrated antitumor activity and a manageable safety profile in previous clinical studies, including a biomarker-driven phase 1/2 study in iCCA patients,9 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting two clinical studies with derazantinib. The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA. It comprises one cohort of patients with FGFR2 gene fusions and another cohort of patients with mutations or amplifications.10 The second study, FIDES-02, is a phase 1/2 study evaluating derazantinib alone and in combination with Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®)11 in patients with advanced urothelial cancer, including metastatic, or recurrent surgically unresectable disease, expressing FGFR genetic aberrations.12.
Basilea in-licensed derazantinib from ArQule Inc, a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
About lisavanbulin (BAL101553)
Basilea's oncology drug candidate lisavanbulin (BAL101553, the prodrug of BAL27862)13 is being developed as a potential therapy for diverse cancers.1, 14, 15 In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.16,17, 18 Lisavanbulin efficiently distributes to the brain, with anticancer activity in glioblastoma models.19, 20, 21 In preclinical studies, end-binding protein 1 (EB1) was identified as a potential response-predictive biomarker in glioblastoma models.21 The active moiety BAL27862 binds to the colchicine site of tubulin, with distinct effects on microtubule organization,22 resulting in the activation of the "spindle assembly checkpoint" which promotes tumor cell death.23
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Derazantinib and its uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
- ClinicalTrials.gov identifier: NCT02490800
- T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), e0162594
- R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology 2017 (113), 256-267
- T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research 2016 (22), 259-267
- P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C12
- M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer 2017, 5:53
- Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-5069
- E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E4050
- V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. ClinicalTrials.gov identifier: NCT01752920
- FIDES-01: ClinicalTrials.gov identifier: NCT03230318
- Tecentriq® ist eine eingetragene Marke von Hoffmann-La Roche AG.
- FIDES-02: ClinicalTrials.gov identifier: NCT04045613.
- J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity. American Association for Cancer Research (AACR) annual meeting 2011, abstract 1347; Cancer Research 2011, 71 (8 supplement)
- ClinicalTrials.gov identifier: NCT03250299
- ClinicalTrials.gov identifier: NCT02895360
- A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy Oncology 2017 (124), 433-438
- G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. American Association for Cancer Research (AACR) annual meeting 2010, abstract 4412; Cancer Research 2010, 70 (8 supplement)
- F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab. American Association for Cancer Research (AACR) annual meeting 2014, abstract 831; Cancer Research 2014, 74 (19 supplement)
- A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique microtubule-targeted agent with a potential for the treatment of human brain tumors. AACR-NCI-EORTC conference 2009, abstract C233; Molecular Cancer Therapeutics 2009, 8 (12 supplement)
- A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding 'tumor checkpoint controller' BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts. American Association for Cancer Research (AACR) annual meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 supplement)
- R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749
- A. E. Prota, F. Danel, F. Bachmann et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. Journal of Molecular Biology 2014 (426), 1848-1860
- F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. American Association for Cancer Research (AACR) annual meeting 2015, abstract 3789; Cancer Research 2015, 75 (15 supplement)
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
PRESS RELEASE: NACON COMPLETES ITS VIDEO GAME DEVELOPMENT UNIT: ACQUISITION OF NEOPICA19.10.2020 17:45:10 CEST | Press release
Press release Lesquin, 19 October 2020 18:00hrs ACQUISITION OF NEOPICA NACON COMPLETES ITS VIDEO GAME DEVELOPMENT UNIT Nacon announces the signing of an agreement to acquire Neopica, a Belgian video game development studio specialising in sports and life simulation games. Following the acquisition of 5 studios over the last 2 years, this new operation enables Nacon to consolidate its position as a developer-publisher by strengthening its expertise in the production of games in promising genres. Created in 2007 by Peter Vermeulen and Filip Hautekeete, among others, Neopica is a renowned Belgian studio that has developed around sixty games, including a number of casual games designed to appeal to the widest possible audience, particularly children, before moving on to more complex simulation games. Neopica and Nacon have enjoyed a fruitful collaboration for several years. In this respect, Neopica produced the Hunting Simulator 1 & 2 hunting games and the FIA Euro Truck Racing Championshi
Auriant Mining AB (publ.) publicerar verksamhetsuppdatering för 9 månader 202019.10.2020 17:45:00 CEST | Pressemelding
Viktiga händelser: • Den totala guldproduktionen under 9 månader 2020 uppgick till 755 kg (24 285 oz), jämfört med 481 kg (15 467 oz) under 9 månader 2019, en ökning med 57% eller 274 kg (8 818 oz). Malmbaserad guldproduktion vid Tardan ökade från 430 kg (13 812 oz) under 9 månader 2019 till 750 kg (24 112 oz) under 9 månader 2020 eller med 75%; • Guldförsäljning under 9 månader 2020 uppgick till 757 kg (24 322 oz), jämfört med 426 kg (13 696 oz) under 9 månader 2019, en ökning med 331 kg (10 642 oz) eller med 78%; • Volymen av malm som bearbetades genom den nybyggda CIL-anläggningen uppgick till 291 kt med en snitthalt om 2,77 g/t (guld i malmen totalt – 806 kg); • CIL-anläggningen var i drift med beräknad bearbetningskapacitet per arbetstimme (>50 ton/timme) och återvinningsgrad (92,9%); • Lakning på hög avbröts i slutet of december 2019; • Volymen för den brutna malmen uppgick till 274 kt (18% lägre än under samma period föregående år). Arbetsvolymen för avrymningen uppgick till 684
EVS Broadcast Equipment reports update of share buyback program19.10.2020 17:45:00 CEST | Press release
Publication on Octobre 19, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between October 12, 2020 and October 16, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)12/10/20202,50014.058114.3013.88 35,145 13/10/20202,50014.076014.2213.94 35,190 14/10/20202,50013.825214.0013.70 34,563 15/10/20202,50013.552013.6013.52 33,880 16/10/20202,25213.402113.5013.30 30,182 Total12,252 13.7904 14.30 13.30 168,960 As of October 16, 2020, and since the start of the buyback program, EVS has bought 302,916 shares at an average price of EUR 15,0557, representing in total EUR 4,560,617. After aforementioned transactions the tota
Auriant Mining AB (publ.) publishes 9m 2020 operational update19.10.2020 17:45:00 CEST | Press release
Highlights: • 9m 2020 total gold productionamounted to 755 kg (24,285 oz), compared to 481 kg (15,467 oz) in 9m 2019, an increase of 57%, or 274 kg (8,818 oz). Hard rock gold production at Tardan increased from 430 kg (13,812 oz) in 9m 2019 to 750 kg (24,112 oz) in 9m 2020, or by 75%; • 9m 2020 gold sales amounted to 757 kg (24,322 oz), compared to 426 kg (13,696 oz) in 9m 2019, an increase of 331 kg (10,642 oz), or 78%; • Volume of ore processed through the newly built CIL plant amounted to 291 thousand tonnes with an average grade of 2.77 g/t (total gold in processed ore – 806 kg); • The CIL plant was operating at projected throughput per working hour (>50 t/hour) and higher recovery rate (92.9%); • Heap leach operations were discontinued at the end of December, 2019; • Ore mined amounted to 274 thousand tonnes (18% less than in the same period of the previous year). Stripping volume in 9m 2020 was 684 thousand m3 (12% less than in 9m 2019); • The average grade in ore mined in 9m 202
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER19.10.2020 16:20:00 CEST | Press release
Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure on 21 October 2020 Certificate:Commercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 21 April 2021 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 12 October 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 21 October 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corr
AT&T and Nokia Drive Industry 4.0 with Private Networks Enabled by CBRS19.10.2020 15:10:00 CEST | Press release
Press Release AT&T and Nokia drive Industry 4.0 with private networks enabled by CBRS 19 October 2020 Dallas, Texas - AT&T* has added Nokia’s end-to-end industrial-grade capabilities to its AT&T Private Cellular Networks solutions. Now businesses across the United States can build private networks through AT&T using Citizens Broadband Radio Service (CBRS) spectrum and Nokia infrastructure. Both Nokia Digital Automation Cloud and Modular Private Wireless platforms will be offered by AT&T. Private networks are increasingly important for businesses – especially in Industry 4.0 environments with a lot of connected devices, where privacy, data control and performance are all crucial. AT&T’s on-premises edge portfolio, which already includes 5G-capable AT&T Multi-Access Edge Computing (MEC), is expanding to offer these additional private cellular solutions with Nokia to meet those Industry 4.0 needs. This is a great solution for enterprise customers – including manufacturing, logistics, ener